Seving Our Customers
Affordable prescription drugs to all people
Hassle-Free Shopping
Reorder Coupons
We respect our customer privacy
Care for your health needs
Live healthy

Fenbendazole Tablets | Parasite Uptake | Medical Information | Fenbendazole Based | Limited Absorption | | Iron and Protein Deficiency | Cell Viability |

Cancer is one of the leading health concerns for many people across the world. Finding effective and safe methods to treat, manage, and prevent various types of cancers is a top priority for medical professionals and researchers. In this blog, we are going to touch on evolving hope in cancer research using Fenbendazole (FENBEN).

What is Fenbendazole?

Fenbendazole is closely similar to Mebendazole which is known to be a very expensive pinworm treatment for kids. Fenbendazole is an affordable alternative to Mebendazole that is available as a dog dewormer (over the counter). Although this medicine has veterinary origins, it has been successfully used to treat many people.

Febendazole capsules are accessible over the counter and have inadequate absorption through the gut thus taking it after a meal helps increase the bioavailability. Some patients open the capsules and sprinkle the medicine onto their meals directly.

This widely used anti-parasitic compound promises to be a supplemental anti-cancer treatment. The probability of repurposing a drug that is already approved and easily accessible shows a motivating progression for cancer treatments.

The Role of Febendzaole in Cancer Research

This drug first emerged in 1974. It eradicates parasites and also holds anti-cancer properties with mild side effects as observed after using it extensively. It successfully shrinks various types of tumors and brings positive differences when used in combination with traditional treatments (chemotherapy and radiation therapy) without disturbing them.

Fenbendazole is being used worldwide now. In addition to eradicating parasites, research demonstrates that Fenbendazole also appears to be a promising anti-cancer agent. Many doctors observed positive outcomes of Febendazole with minimal side effects when used in most patients.

Research reveals Fenbendazole can encourage tumor regression across various types of cancer. Moreover, it appears well suited to traditional methods such as traditional and chemotherapy when used in combination.

Just like many chemotherapy drugs, Fenbendazole can effectively combat cancer cells but with fewer adverse effects and less toxicity. Many pharmaceutical companies are investing in top-notch placebo-controlled studies to get more out of this drug.

How Does It Work?

Fenbendazole acts against parasites by impeding microtubule production. Microtubules are structural elements of cells that allow intracellular transport. The microtubule trouble also pertains to cancer cells which depend on these structures to sustain their speedy uncontrolled multiplication. Febenedazole prevents mitosis through the same mechanism as it kills parasites.

Fenbendazole hits tumors in many ways:

  • It triggers programmed cell death (apoptosis) by causing cell cycle arrest through microtubule disruption.

  • It reactivates the p53 gene which is a strong tumor suppressor. It restores the function of the p53 gene. Humans do not contain much of this gene however Febendazole helps initiate it.

  • It limits the glucose uptake of cancer cells. High consumption of glucose powers the uncontrolled growth of tumors. Fenbendazole seems to limit this major energy source by diminishing glucose transporters that famish cells of division-enabling sugars.

  • Unlike traditional chemotherapy medicines, malignant cells appear unable to be resistant to Fenbendazole with extended use. It allows long-term use of this drug without losing its effectiveness.

Additionally, cancer cells majorly become chemoresistant through P-glycoproteins which are special pumps ejecting anticancer drugs from the cells before they start working. As per the research malignant cells do not recognize Fenbendazole as a compound to expel through these pumps. Thus unlike other drugs, Fenbendazole stays inside the cancer cells retaining its long-term potency by sidestepping efflux by P-glycoproteins.

Human Cancer Treatment with Fenbendazole

  fenbendazole tablets | Drug Induced Liver Injury | Carbohydrate Metabolism | Cell Lysates | Tumor Volumes | Ongoing Research |

In oncology, developments are usually astonishing and enlightening. One such surprising possibility is Fenbendazole. Presently, a substantial upturn has been noticed in research towards comprehending the inhibitory effects of Fenbendazole on cancer cells.

The medical community’s attention peaked on this medication when revolutionary research demonstrated its aptitude to obstruct tumorigenesis. Fenbendazole is placing itself to be a considerable contender in cancer research by interrupting the division of cancer cells which is a vital process in cancer progression.

Researchers and medical professionals commenced investigating the potential of Fenbendazole in cancer treatment due to its established effect on tubulin polymerization inhibition. Tubulin polymerization is a vital process in cancer cell proliferation and growth. In simple words, Fenbendazole can delay cancer cell growth and upset their lifecycles developing a new frontier in cancer therapy.

Fenbendazole for Pancreatic Cancer Treatment

Pancreatic cancer is among the most uncompromising types of cancer with low survival rates. This condition is recognized for its late-stage diagnosis and limited treatments. Thus researchers are continuously searching for new treatments to manage this condition.

Antiparasitic drugs including Fenbendazole have grabbed the attention of researchers reviewing pancreatic cancer. In initial studies, they have demonstrated the potential to constrain the progress and spread of cancer cells. Further research is required to determine the safety and success of human-based clinical trials.

Microtubule Inhibitor

Though the precise mechanisms behind the potential anti-cancer effects of Fenbendazole are being studied, existing research revealed that Fenbendazole can disrupt microtubule function that involves cell division and growth. This drug inhibits the division and proliferation of cancer cells by interfering with microtubule function.

Clinical Trials

Presently, limited data is available regarding ongoing clinical trials, particularly investigating Fenbendazole in cancer treatment. Most research has been preclinical model-based or observational studies in cell culture and animal models.

These clinical trials aim to determine the suitable dosage and treatment regimen of Fenbendazole for various cancers, evaluate its success in contrasting standard treatments, and determine its safety in patients with pancreatic cancer.

Anti-Cancer Effects Of Fenbendazole On 5-Fluorouracil-Resistant Colorectal Cancer Cells

Recently, Benzimidazole anthelmintic agents have been repurposed to combat cancer resistance to established therapies. Several cell death pathways were explored in 5-fluorouracil-resistant colorectal cancer cells to assess the anti-cancer properties of Benzimidazole.

Flow cytometry assays were performed for cell death and cell cycle to investigate the anti-cancer properties of Benzimidazole. Fenbendazole demonstrated higher susceptibility to 5-fluorouracil-resistant SNU-C5 cells as compared to Albendazole and was used in ensuing experiments.

Flow cytometry discovered that Fenbendazole notably tempts apoptosis and cell cycle arrest at the G2/M phase in both cells. 5-fluorouracil-resistant SNU-C5 cells demonstrated condensed autophagy, improved ferroptosis, and ferroptosis-augmented apoptosis, and reduced activation of caspase-8 and p53 when compared with wild-type SNU-C5 cells.

These outcomes advocate that Fenbendazole can be a budding alternative treatment option in 5-fluorouracil-resistant cancer cells and the anticancer impact of Fenbendazole does not need p53 in 5-fluorouracil-resistant SNU-C5 cells.

Fenbendazole: A Moderate Microtubule Destabilizing Agent That Causes Cancer Cell Death By Modulating Multiple Cellular Pathways

Breast Cancer | Cell Extracts | Cells Treated | Cell  Lines | Anticancer Agents | Molecular Mechanisms | Colony Formation Assay |

A Benzimidazole agent is a safe and reasonable anthelmintic medication holding competent anti-proliferative properties. These anticancer agents are non-toxic to normal cells. Free tubulin stimulates mitochondrial function in cancer cells. Fenbendazole shows an adequate affinity for mammalian tubulin and employs cytotoxicity to human cancer cells at micromolar concentrations.

Concurrently it allowed mitochondrial translocation of p53 genes and successfully inhibited glucose uptake. It congested the progression of human xenografts in a nude mice model when mice were administered oral Fenbendazole.

The outcomes and the information from previous studies show that Fenbendazole is a noble microtubule intrusive agent that presents anti-neoplastic activity and can be investigated as a probable therapeutic agent due to its effects on multiple cellular pathways leading to the successful eradication of cancer cells.

Fenbendazole is a broad-spectrum anthelmintic drug approved to treat several animal species. It is known to have an extreme safety margin and better toleration in most species. In experimental animals, it has shown a meager degree of toxicity and better safety.

As per this study, Fenbendazole shows moderate microtubule depolymerization towards human cancer cells however it holds a potent antitumor effect as seen in in vitro and in vivo experiments. This study specifies that this drug exerts its antitumor activity by interrupting microtubule dynamics, activating p53 genes, and modulation of the genes involved in multiple cellular pathways. Treatment with Fenbendazole also decreased glucose uptake in cancer cells because of the down-regulation of GLUT transporters and core glycolytic enzymes.

The tumorigenesis process comprises many genes and proteins modifying various cell signaling pathways, single target drugs display limited effectiveness and may develop drug resistance. Therefore, the agents with multiple cellular targets are expected to have better efficacy besides the ability to circumvent the possibility of developing resistance.

On the whole, the current works suggest a multidrug effect of Fenbendazole on cancer cells causing cell death. That means Fenbendazole possesses a potential therapeutic application against cancer cells.

Fenbendazole Destabilizes Tubulin Network in Human Non-Small Cell Lung Cancer Cells

In vitro studies performed using enhanced extracts of helminthic and mammalian tubulin revealed that tubulin is the foremost molecular tagent of Benzimidazoles. Thus, to investigate the impact of Fenbendazole on the mammalian microtubule network, human non-small cell lung carcinoma A549 cells were treated with 1 uM  Fenbendazole for 24 hours and processed for immunofluorescence employing α tubulin antibody.

Colchicine was utilized as a positive regulator. Outcomes revealed that Fenbendazole treatment caused a limited modification in the microtubule network. The microtubule cage surrounding the nucleus seemed to have lost its intactness when compared with the control mock-treated cells. However, this alteration in the organization was not as in colchicine treatment, which presented comprehensive depolymerization of microtubules into tubulin subunits.

This information advocates that Fenbendazole causes a deformed microtubule framework of the cells. The anthelmintic drug induces mitotic arrest and cell death by polymerizing tubulin in non-small cell lung cancer cells.

Fenbendazole Is Not A P-Glycoprotein Inhibitor(P-gp)

Overcoming drug resistance is a major challenge in cancer treatment. Multidrug resistance (MDR) due to the overexpression of the MDR-1 gene that encrypts P-gp is a vital mechanism of drug resistance resulting in a cross-resistance to multiple drug classes.

However, the efforts to constrain P-gp have not shown satisfying outcomes because of inevitable side effects. Thus the development of new anti-proliferative agents that are not substrates of P-gp can be an effective way to overcome drug resistance.

The inhibition of cancer cell progression by Fenbendazole was tested in the availability of a P-gp inhibitor verapamil. The outcomes demonstrated that P-gp inhibition by verapamil did not improve the inhibitory effect of Fenbendazole on cancer cell proliferation.

Fenbendazole Treatment In Early G2/M Block Followed By Cell Death

Cell Number | Cytochrome c | Independent Experiments | Target Organelles | Rats Infected | Protein Deficiency | eur j cancer |

As tubulin polymerization inhibition blocks cell-cycle progression and may prompt mitotic catastrophe, the influence of Fenbendazole on the progression of the cell cycle is investigated.

For 48 hours, A549 cells were coordinated by serum starvation and treated with 1uM Fenbendazole at different time intervals. The results suggest an early boost of cyclin B1/CDK1 levels in Fembendazole treated cells.

The results confirm that Fenbendazole induced cell cycle arrest during the mitotic phase in human nonsmall cell lung cancer cells. The number of apoptotic cells improved in a time-based manner with a concurrent reduction in cyclin B1 levels.

The cyclin B1 levels reduce further at 40 and 48 hours with Fenbendazole treatment conforming to a further increase in the number of apoptotic cells. It suggests that A549 cells underwent mitotic exit accompanied by cell death with Fenbendazole use. Concludingly this information shows that Fenbendazole causes cell cycle arrest and mitotic cell death consistently due to its microtubular inhibtion effect.

Fenbendazole Cancer Therapy: Things to Remember

  • It should be taken after a meal to improve the absorption of this medicine.

  • It may take up to four months to show noticeable anti-cancer effects.

  • Generally, it is compatible with surgery, radiation therapy, and chemotherapy.

  • Take it till the prescribed period even if your condition improves, tumors may come back easily without continuous treatment, particularly the aggressive types.

  • Frequently monitor relevant tumor markers and go for scans to evaluate regression.

  • Usually, the side effects are very unlikely which include diarrhea that happens when the cancer patient is given higher doses.

  • It may encourage tumor radiosensitivity improving the effectiveness of radiation.

  • If the liver enzymes rise, pause the treatment and resume it after 2 weeks.

Wrapping Up

The effectiveness and tolerance of Fenbendazole in humans have been expansively studied due to its successful veterinary use. Preclinical studies show that the antiparasitic drug Fenbendazole has the potential for treating and managing various types of cancers. Many clinical trials and real-life experiences have reported that it is well tolerated by cancer patients with minimal side effects. The reported side effects include mild gastrointestinal disturbances which resolve without any intervention. Make sure you always consult a healthcare provider before taking any medicine.

Frequently Asked Questions

Is Fenbendazole a chemo drug?

Fenbendazole is an antiparasitic medication, not a chemotherapy drug. It is successfully used against many parasitic infections in animals.

Is fenbendazole a safe medicine?

The safety of this drug is well established. Make sure you use it as prescribed by your doctor and take it for the recommended duration. Do not change the dose until your healthcare provider tells you.

Is it administered orally?

Fenbendazole is available as oral granules and liquid suspension that should be taken by mouth. Suspension should be measured carefully to ensure the correct recommended dose. It is advised to take this medicine with food to avoid gastrointestinal upset.







Fast Delivery